7-甲氧基-1-茚胺 | 1032279-33-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 中文名称: 7-甲氧基-1-茚胺
• 英文名称: 7-Methoxy-2,3-dihydro-1H-inden-1-amine
• CAS: 1032279-33-6
• 化学式: C₁₀H₁₃NO
• 分子量: 163.22
• InChiKey: RWAJCHDFYSLZND-UHFFFAOYSA-N

物化性质

• 沸点：
  264.3±40.0 °C(Predicted)
• 密度：
  1.087±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-氯-5-硝基喹啉 、 7-甲氧基-1-茚胺 在 H+ 作用下， 生成 rac-N2-(7-methoxy-indan-1-yl)-quinoline-2,5-diamine
  参考文献：
  名称：

  2-AMINOQUINOLINE DERIVATIVES

  摘要：

  本发明涉及2-氨基喹啉衍生物，特别是公式（I）中所述的化合物，其中R1和R2如本文所述，包含这种化合物的制药组合物以及其制造方法。本发明的化合物是5-HT5A受体拮抗剂，可用于预防和/或治疗抑郁症，焦虑症，精神分裂症，惊恐症，广场恐惧症，社交恐惧症，强迫症，创伤后应激障碍，疼痛，记忆障碍，痴呆症，饮食行为障碍，性功能障碍，睡眠障碍，药物滥用，帕金森病等运动障碍，精神障碍或肠道障碍的治疗。

  公开号：

  US20090227584A1
• 作为产物：
  描述：

  7-methoxy-indan-1-one oxime 在 钯 908108-58-7 、 (E)-oxime 179899-16-2 、 乙醇 作用下， 以 乙醇 为溶剂， 23.0 ℃ 、13.51 MPa 条件下， 反应 16.0h， 以to give the title compound as a brown oil (2.7 g, 64%)的产率得到7-甲氧基-1-茚胺
  参考文献：
  名称：

  2-AMINOQUINOLINES

  摘要：

  本发明涉及式I的2-氨基喹啉衍生物，其中R1、R2、R3、R4、R5、R6、A和n如规范和权利要求所定义，它们的用途是5-HT5A受体拮抗剂，它们的制造以及含有它们的制药组合物。

  公开号：

  US20090227570A1

文献信息

• QUINOLINES
  申请人：Kolczewski Sabine

  公开号：US20080146567A1

  公开（公告）日：2008-06-19

  The present invention relates to 2-Aminoquinoline derivatives of general formula I and pharmaceutically-acceptable acid-addition salts thereof, wherein R 1 , R 2 and X are as defined in the specification. The compounds may be used as 5-HT 5A receptor antagonists. The present invention relates also to processes for making such a compound and a pharmaceutical composition comprising such a compound. Compounds of the present invention are useful in the prevention and/or treatment of anxiety depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain, memory disorders, dementia, disorders of eating behaviors, sexual dysfunction, sleep disorders, withdrawal from abuse of drugs, motor disorders such as Parkinson's disease, psychiatric disorders and gastrointestinal disorders.

  本发明涉及一般式I的2-氨基喹啉衍生物及其药用可接受的酸盐，其中R1、R2和X如规范中所定义。这些化合物可以用作5-HT5A受体拮抗剂。本发明还涉及制备这种化合物的方法以及包含这种化合物的药物组合物。本发明的化合物在预防和/或治疗焦虑抑郁症、焦虑障碍、精神分裂症、惊恐障碍、广场恐惧症、社交恐惧症、强迫症、创伤后应激障碍、疼痛、记忆障碍、痴呆症、饮食行为障碍、性功能障碍、睡眠障碍、戒除药物滥用、帕金森病等运动障碍、精神障碍和胃肠道障碍方面具有用处。
• SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS
  申请人：Chow Ken

  公开号：US20080255239A1

  公开（公告）日：2008-10-16

  Therapeutic compounds, and methods, compositions, and medicaments related thereto are disclosed herein.

  本文揭示了治疗化合物、方法、组合物和相关药物。
• 6-SUBSTITUTED BENZOXAZINES
  申请人：Kolczewski Sabine

  公开号：US20100063037A1

  公开（公告）日：2010-03-11

  The present invention is concerned with 6-substituted benzoxazine derivatives of formula (I) wherein X, Y, R 1 and R 2 are as described herein, their manufacture, and pharmaceutical compositions containing them. The active compounds of the present invention are 5-HT 5A receptor antagonists, useful in the prevention and/or treatment of depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain, memory disorders, dementia, disorders of eating behaviors, sexual dysfunction, sleep disorders, abuse of drugs, motor disorders, Parkinson's disease, psychiatric disorders or gastrointestinal disorders.

  本发明涉及公式(I)的6-取代苯并噁嗪衍生物，其中X、Y、R1和R2如本文所述，其制备方法，以及含有它们的药物组合物。本发明的活性化合物是5-HT5A受体拮抗剂，在预防和/或治疗抑郁症、焦虑障碍、精神分裂症、恐慌障碍、广场恐惧症、社交恐惧症、强迫性障碍、创伤后应激障碍、疼痛、记忆障碍、痴呆症、进食行为障碍、性功能障碍、睡眠障碍、药物滥用、运动障碍、帕金森病、精神障碍或胃肠道障碍的预防和/或治疗中有用。
• Novel aminotransferase, gene encoding the same, and method of using them
  申请人：Ito Noriyuki

  公开号：US20100285544A1

  公开（公告）日：2010-11-11

  The invention relates to a novel aminotransferase, DNA encoding the enzyme, a recombinant vector into which the DNA has been introduced, and a transformant into which the vector has been introduced. Further, the invention also relates to a method for producing an optically active amino compound utilizing the enzyme or transformant. The aminotransferase of the invention has an ability of efficiently converting a ketone compound, particularly a cyclic ketone compound to an optically active amino compound. According to the invention, a method for efficiently producing an optically active amino compound, particularly an optically active cyclic amino compound is provided.

  本发明涉及一种新型氨基转移酶、编码该酶的DNA、已引入该DNA的重组载体以及已引入该载体的转化菌株。此外，本发明还涉及一种利用该酶或转化菌株生产光学活性氨基化合物的方法。本发明的氨基转移酶能够高效地将酮类化合物，尤其是环状酮类化合物转化为光学活性氨基化合物。根据本发明，提供了一种高效生产光学活性氨基化合物，尤其是光学活性环状氨基化合物的方法。
• Aminoindan derivatives
  申请人：Yissum Research Development Company of the Hebrew University of Jerusalem

  公开号：US20020188020A1

  公开（公告）日：2002-12-12

  This invention is directed to compounds of the following formula: 1 wherein when a is 0, b is 1 or 2; when a is 1, b is 1, m is from 0-3, X is O or S, Y is halogeno, R 1 is hydrogen C 1-4 alkyl, R 2 is hydrogen, C 1-4 alkyl, or optionally substituted propargyl and R 3 and R 4 are each independently hydrogen, C 1-6 alkyl, C 6-12 aryl, C 6-12 aralkyl each optionally substituted. This invention is also directed to the use of these compounds for treating depression, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome, Alzheimer's Disease and other dementia's such as senile dementia, dementia of the Parkinson's type, vascular dementia and Lewy body dementia. This invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

  本发明涉及以下式子的化合物：1其中当a为0时，b为1或2；当a为1时，b为1，m为0-3，X为O或S，Y为卤素，R1为氢C1-4烷基，R2为氢，C1-4烷基，或可选取代的丙炔基，而R3和R4各自独立地为氢，C1-6烷基，C6-12芳基，C6-12芳基烷基，均可选取代基。本发明还涉及使用这些化合物治疗抑郁症、注意力缺陷障碍（ADD）、注意力缺陷多动障碍（ADHD）、托瑞特综合症、阿尔茨海默病和其他痴呆症，如老年性痴呆、帕金森型痴呆、血管性痴呆和Lewy体痴呆。本发明还涉及一种制药组合物，包括上述定义的化合物的治疗有效量和药学上可接受的载体。